Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score

Oncologist

Volumn 16, Issue 10, 2011, Pages 1359-1366

  Kamal, Arif H ^a   Loprinzi, Charles L ^b   Reynolds, Carol ^b   Dueck, Amylou C ^b   Geiger, Xochiquetzal J ^c   Ingle, James N ^b   Carlson, Robert W ^d   Hobday, Timothy J ^b   Winer, Eric P ^e   Goetz, Matthew P ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Recurrence disease management

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MEDICAL SPECIALIST; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROGNOSIS; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL GROWTH PROCESSES; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 80054794452     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0048     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ernst MF, Voogd AC, Coebergh JW et al. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 2004;100:1337-1344.
3. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352:930-942.
4. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-1667.
5. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-1506.
6. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
7. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
8. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
9. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
10. Carlson RW, Allred DC, Anderson BO et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:122-192.
11. Edén P, Ritz C, Rose C et al. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004;40:1837-1841.
12. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
13. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010;28:1829-1834.
14. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
15. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. Hoboken, NJ: Wiley, 2003:1-800.
16. Gregg X, Belnap T, Rowley R et al. Experience with the use of the Oncotype DX® gene assay test in a multicenter community-based healthcare system. Presented at the 32nd Annual Cancer Therapy & Research Center-American Association of Cancer Research San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9-13, 2009.
17. Acs G, Esposito N et al. The effect of Oncotype DX® recurrence score on treatment recommendations for patients with early stage estrogen receptor positive breast cancer. Presented at the 32nd Annual Cancer Therapy&Research Center-American Association of Cancer Research San Antonio Breast Cancer Symposium. San Antonio, Texas, December 9-13, 2009.
18. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28: 1671-1676.
19. Foster JA, Abdolrasulnia M, Doroodchi H et al. Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer. J Natl Compr Canc Netw 2009;7:697-706.
20. Graham ID, Brouwers M, Davies C et al. Ontario doctors' attitudes toward and use of clinical practice guidelines in oncology. J Eval Clin Pract 2007; 13:607-615.
21. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005; 11:313-324.